The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...